

🌐 English🌐 Central/Eastern Europe, Middle East & Africa - English

(<https://www.medtronic.com/me-en/index.html>)

Resolute Onyx DES

for coronary artery disease

Resolute Onyx™ is a drug-eluting stent (DES) that's different by design, optimised for complex PCI, and proven safe and effective in real-world, high bleeding risk patients on 1-month dual antiplatelet therapy (DAPT).¹

MENU

[Download Brochure](/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/Resolute-Onyx-Product-Brochure.pdf) (opens new window) (/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/Resolute-Onyx-Product-Brochure.pdf)

Resolute Onyx DES is different by design to address your DES needs and a wide range of patient anatomies. It features:

- Best-in-class deliverability²
- Enhanced visibility with thinner struts²
- Smooth side branch access²
- Fast healing³
- The broadest diameter range

Product Features

Best-in-class deliverability

Single-wire design

Resolute Onyx DES is made from a single wire, which gives it a fluid range of motion and provides the flexibility needed for best-in-class deliverability.²

MENU

Sinusoid-formed wire

Helical wrap

Laser-fused

The Only DES Designed from a Single Wire[‡]

Proven components for optimal healing

Watch a short video to learn more about the BioLinx™ polymer.

- Single-wire design provides a fluid range of motion and the conformability needed for superior strut apposition.²
- BioLinx biocompatible polymer provides superior thromboresistance.⁴
- When combined, fast healing occurs as evidenced by nearly 90% strut coverage at 30 days,³ providing the foundation for the Onyx ONE Global Trial.
- The Onyx ONE Global Trial analysed real-world, high bleeding risk patients on 1-month DAPT treated with a Resolute Onyx DES or a BioFreedom™* DCS.
- Results showed Resolute Onyx DES was safe and effective,¹ providing the option to shorten DAPT in patients who are at high bleeding risk.
- Based on these results, Resolute Onyx DES was the first DES CE-indicated for HBR patients on 1-month DAPT.

See the Onyx ONE Data (<https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html>)

MENU

Enhanced visibility with thinner struts

Platinum-iridium core within Resolute Onyx DES increases visibility for accurate stent placement without compromising strut thickness.²

Resolute Onyx cobalt alloy shell and platinum-iridium core

1. Cobalt alloy shell
2. Platinum iridium core

Smooth side branch access

Resolute Onyx DES has round struts to create a smooth passage when accessing the side branch and lower the propensity to catch during bifurcation procedures.²

Rounded strut cross-section

1. Resolute Onyx DES

MENU

Broadest diameter range

- Complex PCI requires a broad DES size matrix to match a wide range of patient anatomies.
- Resolute Onyx is the only DES with diameters ranging from 2.0 mm to 5.0 mm to treat a broad range of coronary vessel sizes.

| Diameter (mm) | Stent Length (mm) | | | | | | | | | Maximum Expansion Capabilities (MSID [†]) (mm) |
|---------------|-------------------|----|----|----|----|----|----|----|----|--|
| | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | |
| 2.00 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | — | — | 3.50 [‡] |
| 2.25 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | 3.50 [‡] |
| 2.50 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | 3.50 [‡] |
| 2.75 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | 4.00 [‡] |
| 3.00 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | 4.00 [‡] |

| | | | | | | | | | | |
|------|---|----|----|----|----|----|----|----|----|-------------------------|
| 3.50 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | 5.00[‡] |
| 4.00 | 8 | 12 | 15 | 18 | 22 | 26 | 30 | 34 | 38 | 5.00[‡] |
| 4.50 | — | 12 | 15 | 18 | 22 | 26 | 30 | — | — | 6.00[‡] |
| 5.00 | — | 12 | 15 | 18 | 22 | 26 | 30 | — | — | 6.00[‡] |

Product Details

| Stent Length (mm) | Stent Length (mm) | | | | | | |
|-------------------|-------------------|-------------|-------------|-------------|-------------|-------------|----|
| | 8 | 12 | 15 | 18 | 22 | 26 | 30 |
| 2.00 | RONYX20008X | RONYX20012X | RONYX20015X | RONYX20018X | RONYX20022X | RONYX20026X | F |
| 2.25 | RONYX22508X | RONYX22512X | RONYX22515X | RONYX22518X | RONYX22522X | RONYX22526X | F |
| 2.50 | RONYX25008X | RONYX25012X | RONYX25015X | RONYX25018X | RONYX25022X | RONYX25026X | F |
| 2.75 | RONYX27508X | RONYX27512X | RONYX27515X | RONYX27518X | RONYX27522X | RONYX27526X | F |
| 3.00 | RONYX30008X | RONYX30012X | RONYX30015X | RONYX30018X | RONYX30022X | RONYX30026X | F |
| 3.50 | RONYX35008X | RONYX35012X | RONYX35015X | RONYX35018X | RONYX35022X | RONYX35026X | F |
| 4.00 | RONYX40008X | RONYX40012X | RONYX40015X | RONYX40018X | RONYX40022X | RONYX40026X | F |

| | | | | | | | |
|-------------|-----|-------------|-------------|-------------|-------------|-------------|---|
| | | | | | | | |
| 4.50 | N/A | RONYX45012X | RONYX45015X | RONYX45018X | RONYX45022X | RONYX45026X | F |
| 5.00 | N/A | RONYX50012X | RONYX50015X | RONYX50018X | RONYX50022X | RONYX50026X | F |

Maximum expansion capabilities

Reference only in markets where the Resolute Onyx coronary stent and the 0.25 mm expansion have been approved.

Additional Resources

Onyx ONE Global Trial

First randomised, 1-month DAPT trial comparing a DES to a DES in ~2000 high bleeding risk patients on 1-month DAPT.

[Review the Data \(https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html\)](https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html)

Resolute Onyx DES is optimised for complex PCI

Resolute Onyx DES design exclusives make it ideal for complex cases.

[See How \(https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/complex-lesions.html\)](https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/complex-lesions.html)


Bifurcation education

View five techniques that highlight Resolute Onyx DES through endoscopic imaging captured inside an isolated and reanimated beating porcine heart.

[Visit and Bookmark \(opens new window\) \(/content/dam/medtronic-com/global/HCP/elearning/bifurcation-exploration/backup/story_html5.html\)](/content/dam/medtronic-com/global/HCP/elearning/bifurcation-exploration/backup/story_html5.html)

MENU

Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx™ polymer contributes to minimal inflammation, low thrombotic risk,⁵ as well as rapid, complete, and functional endothelial healing.^{§4}

 **Onyx One Results Brochure** (.pdf) (opens new window) (/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML_Onyx_ONE_Results_Brochure.pdf)

This brochure presents clinical evidence about Onyx One.
307KB

(opens new window) (/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML_Onyx_ONE_Results_Brochure.pdf)

Request more information

[Contact us \(/me-en/about/contact-us.html?src=cardiovascular.html\)](/me-en/about/contact-us.html?src=cardiovascular.html)

*

As per April 2021.

†

Medtronic and Medtronic logo are trademarks of Medtronic. Third-party trademarks ("™†") belong to their respective owners. All other brands are trademarks of a Medtronic entity.

‡

Including Resolute Integrity™ DES, part of the Medtronic DES portfolio.

§

porcine models.

MENU

References

1

Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*. March 26, 2020;382(13):1208-1218.

2

Based on bench test data on file at Medtronic. May not be indicative of clinical performance.

3

Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Adv Interv Cardiol*. 2019;15(2):143-150.

4

Jinnouchi H, Sato Y, Cheng Q, et al. *Int J Cardiol*. March 2021;327:52-57.



(mailto:?



body=https%3A%2F%2Fwww.me
dtronic.com%2Fme-
en%2Fhealthcare-
professionals%2Fproducts%2Fca
rdiovascular%2Fstents%2Fresolu
te-onyx-des.html)

MENU



[Patients and Caregivers](#)

[Overview \(https://www.medtronic.com/me-en/your-health.html\)](https://www.medtronic.com/me-en/your-health.html)

[Healthcare Professionals](#)

[Overview \(https://www.medtronic.com/me-en/healthcare-professionals.html\)](https://www.medtronic.com/me-en/healthcare-professionals.html)

[Our company](#)

[Key facts \(https://www.medtronic.com/me-en/our-company/key-facts.html\)](https://www.medtronic.com/me-en/our-company/key-facts.html)

[Leadership \(https://www.medtronic.com/me-en/our-company/leadership.html\)](https://www.medtronic.com/me-en/our-company/leadership.html)

[Mission \(https://www.medtronic.com/me-en/our-company/mission.html\)](https://www.medtronic.com/me-en/our-company/mission.html)

[Career Opportunities \(/me-en/about/careers.html\)](/me-en/about/careers.html)

[Locations \(https://www.medtronic.com/me-en/our-company/locations.html\)](https://www.medtronic.com/me-en/our-company/locations.html)

[Our impact](#)

[Overview \(https://www.medtronic.com/me-en/our-impact.html\)](https://www.medtronic.com/me-en/our-impact.html)

[Privacy Statement \(/me-en/privacy-statement.html\)](/me-en/privacy-statement.html)

[Terms of Use \(/me-en/terms-of-use.html\)](/me-en/terms-of-use.html)

[Contact \(https://www.medtronic.com/me-en/about/contact-us.html\)](https://www.medtronic.com/me-en/about/contact-us.html)

MENU

UC201804678a EE Last Updated February 2023 © 2023 Medtronic